Article
Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysis.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology - 1 Feb 2022
Di Bona Danilo, Crimi Claudia, D'Uggento Angela Maria, Benfante Alida, Caiaffa Maria Filomena, Calabrese Cecilia, Campisi Raffaele, Carpagnano Giovanna Elisiana, Ciotta Domenico, D'Amato Maria, Pelaia Corrado, Pelaia Girolamo, Pellegrino Simona, Scichilone Nicola, Scioscia Giulia, Ribecco Nunziata, Spadaro Giuseppe, Valenti Giuseppe, Vatrella Alessandro, Crimi Nunzio, Macchia Luigi
Abstract excerpt
BACKGROUND: Benralizumab is effective in severe eosinophilic asthma (SEA), but suboptimal responses are observed in some patients. Although several factors have been associated with benralizumab response, no cluster analysis has yet been undertaken to identify different responsiveness sub-phenotypes. OBJECTIVE: To identify SEA sub-phenotypes with differential responsiveness to benralizumab. METHODS: One hundred...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.